As of August 2025, Novo considered expanding this cash sales model to other markets
Figures Abstract Glucagon-like peptide-1 (GLP-1) released from intestinal L cells in response to nutrients has many physiological effects but particularly enhances glucose-dependent insulin release through the GLP-1 receptor (GLP-1R)
Biomarkers in cancer detection, diagnosis, and prognosis
Self-pay rates for available GLP-1s start at: Wegovy (pill) $149/mo Foundayo (orforglipron) $149/mo Ozempic $199/mo Wegovy $199/mo Zepbound $299/mo Saxenda Cost varies depending on insurance coverage Pricing reflects self-pay medication costs only, if prescribed, and does not include the cost of a WW membership
Medical screening: Contraindications like thyroid cancer history or pancreatitis must be screened before prescribing
Tirzepatide is a dual agonist (GIP and GLP-1), which clinical trials indicate causes greater weight loss (up to 20-21%) than the GLP-1-only agonist Semaglutide (around 15%), though both are effective tools for managing obesity